Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial

Gavilá, J., Oliveira, M., Pascual, T., Perez-Garcia, J., Gonzàlez, X., Canes, J., … Prat, A. (2019). Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial. BMC Medicine, 17(1). https://doi.org/10.1186/s12916-018-1233-1